Determining optimal yet feasible endpoints for clinical trials evaluating pharmacologic agents for NAFLD and NASH is complex, because of the chronic nature of the disease, with typically slow progression to clinically significant outcomes.34 Subsequently, relevant and acceptable surrogate endpoints need to demonstrate efficacy before the onset of long-term complications
In an audience packed with senior R&D leadersincluding over 10 from Eli Lilly, alongside key figures from Novo Nordisk, AstraZeneca, Roche, Boehringer Ingelheim, and others the realization dawned that a traditional pharma giant had officially evolved into the first longevity pharma company
The scientific understanding of how the microbiome dictates the severity of post-viral syndromes has advanced exponentially in recent years
Choose the time that works best for your schedule and stick with it
The estimates above are based on trial completion dates and standard regulatory timelines